Immuneering appoints Andrew Gengos as CFO, effective July 16, 2026

Immuneering Corp

Andrew Gengos named CFO and Treasurer, replacing Mallory Morales who remains SVP Finance, CAO.
Gengos gets base salary of $530,000 and target bonus of 40% of base salary.
Inducement grant of 650,000 stock options under 2025 Employment Inducement Award Plan.
Gengos previously CFO at Terns Pharmaceuticals (Feb 2025-May 2026) and CFO/CBO at LeonaBio.
Gengos' employment includes severance provisions: 12 months salary plus COBRA on qualifying termination.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Gengos

Chief Financial Officer and Treasurer

IMRX · Immuneering Corp

Effective: 2026-07-16
Filed: June 15, 2026, 4:12 PM ET

On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the “Effective Date”).

Role change

Mallory Morales

Senior Vice President Finance, Chief Accounting Officer

IMRX · Immuneering Corp

Effective: 2026-07-16
Successor: Andrew Gengos
Filed: June 15, 2026, 4:12 PM ET

The Board also designated Mr. Gengos as the Company’s principal financial officer as of the Effective Date, succeeding Mallory Morales in such role. In her ongoing role as Senior Vice President Finance, Chief Accounting Officer, Ms. Morales will continue to serve as the Company’s principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Gengos was appointed as Chief Financial Officer and Treasurer at Immuneering Corp.

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mallory Morales changed role as Senior Vice President Finance, Chief Accounting Officer at Immuneering Corp.

Action: succeeded as principal financial officer, remains SVP Finance, CAO
Role: Senior Vice President Finance, Chief Accounting Officer

Exact text from the filing

The Board also designated Mr. Gengos as the Company’s principal financial officer as of the Effective Date, succeeding Mallory Morales in such role. In her ongoing role as Senior Vice President Finance, Chief Accounting Officer, Ms. Morales will continue to serve as the Company’s principal accounting officer.

View on SEC.gov

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001790340-26-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.